6/9T9:14 Co. in the News

Companies in the New:

MYGN:

MYGN Myriad Genetics: Flurizan U.S. phase III success appears unlikely - Cowen (48.03 )
Cowen says top-line results from the Flurizan U.S. Phase III Alzheimer's trial should be released this month. Firm's analysis of the available clinical and pre-clinical data, and checks with their clinical and statistical consultants lead firm to conclude that the Phase III trial may show a positive treatment trend, but Flurizan is unlikely to achieve statistically significant efficacy. This expected outcome is consistent with the Street consensus view, so downside to MYGN shares may be limited. While MYGN shares could have 15-25% upside potential vs the market should the Flurizan U.S. Phase III trial succeed, firm believes that is a very low-probability outcome.

ANAD:

ANAD Anadigics: Top pick from the Taiwan Computex Show - Jefferies (12.92 )
Jefferies notes that thee Taiwan Computex Show closes on the high note for exhibitors but a low note on orders. From survey they conducted remain concerned about the low volume of orders concerns that the macro economic factors could dampen demand in 2H 2008. As a result, many customers may delay orders until summer time. Firm's top stock from Computex is Anadigics (ANAD). The push out of the Montevina Notebook platform clearly benefits ANAD who is sole sourced designed in the current Santa Rosa WiFi modules for Notebooks. As a result, they believe the revenue stream for ANAD's WiFi products will see continued traction and stability.